Phase II Study of Evaluating the Efficacy and Safety of Tusamitamab Ravtansine (SAR408701) Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors, including Pancreatic Cancer
The purpose of this trial is to evaluate the safety and efficacy of Tusamitamab ravtansine with and without Gemcitabine in patients with metastatic pancreatic adenocarcinoma.
Study ID: ACT16432
Trial Phase: Phase II
Trial Sponsor: Sanofi
Therapies Used in This Trial: tusamitamab ravtansine